Selpercatinib
Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity[1][2].
Product Specifications
CAS Number
2152628-33-4
Product Name Alternative
LOXO-292
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
RET
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/RET_kinase_inhibitor_1.html
Purity
99.83
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
N#CC1=C2C(C3=CC=C(N4CC(C5)N(CC6=CC=C(OC)N=C6)C5C4)N=C3)=CC(OCC(C)(O)C)=CN2N=C1
Molecular Formula
C29H31N7O3
Molecular Weight
525.60
Precautions
H315, H319, H320
References & Citations
[1]Şentürk R, et, al. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jun 15;1147:122131.|[2]Steven W. Andrews, et al. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors. WO2018071447A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K3901503 1.0 µg DNA
Ppif sgRNA CRISPR Lentivector (Mouse) (Target 2)
Sign In for Pricing
View Details 